

# Changing Treatment Paradigms with Immunotherapy and Targeted Therapy in Advanced Non-Small-Cell Lung Cancer and Head & Neck Cancer

October 27, 2018, Houston, Texas

7:00 AM - 3:45 PM

Houston Marriott at the Texas Medical Center 6580 Fannin Street, Houston, TX 77030; Phone: (713) 796-0080

Program Director: John V. Heymach, MD, PhD

Jointly provided by



Educational Grants: Merck Sharp & Dohme Corp.; AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb

## Statement of Need/Program Overview

This symposium is intended to improve care of patients with non-small cell lung cancer and head & neck cancer by accelerating adoption of new guidelines and evidence-based practice change. The format will include didactic lectures from known opinion leaders, question and answer sessions, and ample opportunity for participant interaction with faculty.

## Target Audience

This symposium is directed primarily to hematologists/oncologists, radiation oncologists, researchers, pharmacists, registered nurses, physician assistants, nurse practitioners and fellows in training interested in new development in non-small cell lung cancer and head & neck cancer. No specific skill or knowledge other than a basic training in hematology/oncology is required for successful participation in this activity.

## Physicians / Nurses / Pharmacists

In support of improving patient care, this activity has been planned and implemented by Amedco LLC and CancerNet. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Amedco LLC designates this live activity for a maximum of 6.5 AMA PRA Category 1 Credits™ for physicians, 6.5 contact hours for nurses and 6.5 knowledge-based contact hours for pharmacists. Learners should claim only the credit commensurate with the extent of their participation in the activity.

## Agenda Topics (Tentative)

- Molecular Profiling in the Treatment of NSCLC: Guidelines from the CAP, IASLC and AMP .....*John V. Heymach, MD, PhD*
- EGFR Inhibitors: Perspective on Molecular Markers and Patient Selection .....*Don L. Gibbons, MD, PhD*
- Emerging Strategies and Challenges Due to Secondary or Acquired EGFR-TKI Resistance .....*Don L. Gibbons, MD, PhD*
- Immunotherapy with PD-1/PD-L1 (Nivolumab, Pembrolizumab, Durvalumab) and Anti CTLA-4 (Ipilimumab) Antibodies in NSCLC .....  
*John V. Heymach, MD*
- Immunotherapy with Anti-PD-L1 (Pembrolizumab) and Combination Therapy Approaches in NSCLC .....*Jianjun Zhang, MD, PhD*
- Overview of Molecular, Histologic Tumor Testing, High Mutational Burden and Implication of Immune Resistance in HPV-associated Head & Neck Cancer .....*Tanguy Seiwert, MD*
- Immunotherapy Options in the Treatment of Metastatic Head & Neck Cancer .....*Tanguy Seiwert, MD*
- Overview of Molecular Targeted Therapy on the Outcome of Early-stage NSCLC Patients with EML4-ALK Fusion Gene and the Application of TKIs .....*Anne Tsao, MD*
- Discuss Emerging Strategies and Challenges Due to Secondary or Acquired Resistance to Small Molecule TKIs in Patients with ALK-rearranged NSCLC .....*Vincent Lam, MD*

**For detailed information on faculty, learning objectives and agenda please refer to the [www.cancernetus.com](http://www.cancernetus.com)**

## REGISTRATION FORM Changing Treatment Paradigms with Immunotherapy and Targeted Therapy in Advanced Non-Small-Cell Lung Cancer and Head & Neck Cancer

First Name \_\_\_\_\_ Middle Initial \_\_\_\_\_ Last Name \_\_\_\_\_

Physician     Pa-C     NP     PhD     Pharmacist     Industry     Nurse     Other

Mailing Address \_\_\_\_\_

City \_\_\_\_\_ State \_\_\_\_\_ Zip Code \_\_\_\_\_

Phone \_\_\_\_\_ Fax \_\_\_\_\_

E-Mail \_\_\_\_\_

Specialty \_\_\_\_\_

### Registration Fee (Registration fee includes buffet breakfast, lunch and syllabus book)

	Early Registration Fee - Up to 10/5/18	Discounted Registration Fee -10/6/18 - 10/20/18	Regular Registration Fee - 10/21/18 - 10/27/18
<input type="checkbox"/> Physicians	\$100.00	\$130.00	\$160.00
<input type="checkbox"/> Nurses, Nurse Practitioners, Physician Assistants	\$75.00	\$95.00	\$115.00
<input type="checkbox"/> Pharmacists, Fellows	\$75.00	\$95.00	\$115.00
<input type="checkbox"/> Industry †	\$350.00	\$400.00	\$450.00

† Person(s) employed by for-profit organizations such as pharmaceutical and biotech companies, and financial institutions

Fax registration to:  
443-267-0016

Mail registration to:  
860 Hebron Pkwy, Suite 1104  
Lewisville, TX 75057

Check box to receive information about Live and Webcast programs. You can unsubscribe at any time.

### No Refund; Substitution is allowed

Payment may be made:  MC     Visa     Discover     Check

Credit Card Number \_\_\_\_\_ Expiration Date \_\_\_\_\_

Name and address (as given on the monthly credit card statement) \_\_\_\_\_

Pharmacist e-profile NABP#: \_\_\_\_\_ Pharmacist DOB (MMDD): \_\_\_\_\_

Signature \_\_\_\_\_

Register online at [www.cancernetus.com](http://www.cancernetus.com)

Please make checks payable to CancerNet. Mail checks to CancerNet, 860 Hebron Pkwy, Suite 1104, Lewisville, TX 75057

To reserve your place for the meeting, please complete the registration form and fax it to 443-267-0016. For questions, please call Brian Waggoner at 972-459-5222 or E-mail: [brianw@cancernetus.com](mailto:brianw@cancernetus.com)

If you wish to be removed from this fax list, please call 1-866-205-9658 ext. 42870.